Trends in HLA antibody screening and identification and their role in transplantation

References

• Cecka JM. The UNOS Scientific Renal Transplant Registry. Clin. Transpl.1–14 (1996).
   PubMedGoogle Scholar
• Takemoto SK, Terasaki PI, Gjertson DW, Cecka JM. Twelve years’ experience with national sharing of HLA-matched cadaveric kidneys for transplantation. N. Engl. J. Med.343(15), 1078–1084 (2000).
   PubMed Web of Science ®Google Scholar
• Gjertson DW, Terasaki PI, Takemoto S, Mickey MR. National allocation of cadaveric kidneys by HLA matching. Projected effect on outcome and costs. N. Engl. J. Med.324(15), 1032–1036 (1991).
   PubMed Web of Science ®Google Scholar
• Terasaki PI, Cho Y, Takemoto S, Cecka M, Gjertson D. Twenty-year follow-up on the effect of HLA matching on kidney transplant survival and prediction of future twenty-year survival. Transplant. Proc.28(3), 1144–1145 (1996).
   PubMedGoogle Scholar
• Beatty PG, Mori M, Milford E. Impact of racial genetic polymorphism on the probability of finding an HLA-matched donor. Transplantation60, 778–783 (1995).
   PubMed Web of Science ®Google Scholar
• Roberts JP, Wolfe RA, Bragg-Gresham JL et al. Effect of changing the priority for HLA matching on the rates and outcomes of kidney transplantation in minority groups. N. Engl. J. Med.350(6), 545–551 (2004).
   PubMed Web of Science ®Google Scholar
• Doxiadis II, de Fijter JW, Mallat MJ et al. Simpler and equitable allocation of kidneys from postmortem donors primarily based on full HLA-DR compatibility. Transplantation83(9), 1207–1213 (2007).
   PubMed Web of Science ®Google Scholar
• Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N. Engl. J. Med.280, 735–739 (1969).
   PubMed Web of Science ®Google Scholar
• Gebel HM, Bray RA. Sensitization and sensitivity: defining the unsensitized patient. Transplantation69(7), 1370–1374 (2000).
   PubMedGoogle Scholar
• Karpinski M, Rush D, Jeffery J et al. Flow cytometric crossmatching in primary renal transplant recipients with a negative antihuman globulin enhanced cytotoxicity crossmatch. J. Am. Soc. Nephrol.12(12), 2807–2814 (2001).
   PubMed Web of Science ®Google Scholar
• Bray RA, Nickerson PW, Kerman RH, Gebel HM. Evolution of HLA antibody detection: technology emulating biology. Immunol. Res.29(1–3), 41–54 (2004).
   PubMedGoogle Scholar
• Ting A, Terasaki PI. Lymphoctye-dependent antibody cross-matching for transplant patients. Lancet1(7902), 304–306 (1975).
   PubMedGoogle Scholar
• Fuller TC, Phelan D, Gebel HM, Rodey GE. Antigenic specificity of antibody reactive in the antiglobulinaugmented lymphocytotoxicity test. Transplantation34(1), 24–29 (1982).
   PubMed Web of Science ®Google Scholar
• Kerman RH, Kimball PM, Van Buren CT et al. AHG and DTE/AHG procedure identification of crossmatch-appropriate donor-recipient pairings that result in improved graft survival. Transplantation51(2), 316–320 (1991).
   PubMedGoogle Scholar
• Sayeh MH. Why do we reject a graft? Role of indirect allo-recognition in graft rejection. Kidney Int.56, 1967–1979 (1999).
   PubMedGoogle Scholar
• Jeannet M, Pinn VW, Flax MH, Winn HJ, Russell PS. Humoral antibodies in renal allotransplantation in man. N. Engl. J. Med.282, 111–117 (1970).
   PubMed Web of Science ®Google Scholar
• Gould DS, Auchincloss H Jr. Direct and indirect recognition: the role of MHC antigens in graft rejection. Immunol. Today20(2), 77–82 (1999).
   PubMedGoogle Scholar
• Kissmeyer-Nielsen F, Olsen S, Petersen VP, Fjeldborg O. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet7465, 662–665 (1966).
   Google Scholar
• Akalin E, Watschinger B. Antibodymediated rejection. Semin. Nephrol.27(4), 393–407 (2007).
   PubMed Web of Science ®Google Scholar
• Bryan CF, Martinez J, Muruve N et al. IgM antibodies identified by a DTT-ameliorated positive crossmatch do not influence renal graft outcome but the strength of the IgM lymphocytotoxicity is associated with DR phenotype. Clin. Transplant.15(Suppl. 6), 28–35 (2001).
   PubMedGoogle Scholar
• Barger B, Shroyer TW, Hudson SL et al. Successful renal allografts in recipients with crossmatch-positive, dithioerythritol-treated negative sera. Race, transplant history, and HLA-DR1 phenotype. Transplantation47(2), 240–245 (1989).
   PubMedGoogle Scholar
• McCalmon RT Jr, Tardif GN, Sheehan MA, Fitting K, Kortz W, Kam I. IgM antibodies in renal transplantation. Clin. Transplant.11(6), 558–564 (1997).
   PubMedGoogle Scholar
• Roelen DL, van Bree J, Witvliet MD et al. IgG antibodies against an HLA antigen are associated with activated cytotoxic T cells against this antigen, IgM are not. Transplantation57(9), 1388–1392 (1994).
   PubMedGoogle Scholar
• Pei R, Wang G, Tarsitani C et al. Simultaneous HLA class I and class II antibodies screening with flow cytometry. Hum. Immunol.5, 313–322 (1998).
   Google Scholar
• Connolly JK, Dyer PA, Martin S, Parrott NR, Pearson RC, Johnson RW. Importance of minimizing HLA-DR mismatch and cold preservation time in cadaveric renal transplantation. Transplantation61(5), 709–714 (1996).
   PubMedGoogle Scholar
• Lee CM, Carter JT, Randall HB et al. The effect of age and prolonged cold ischemia times on the national allocation of cadaveric renal allografts. J. Surg. Res.91(1), 83–88 (2000).
   PubMedGoogle Scholar
• Figueiredo A, Moreira P, Parada B et al. Risk factors for delayed renal graft function and their impact on renal transplantation outcome. Transplant. Proc.39(8), 2473–2475 (2007).
   PubMedGoogle Scholar
• Pei R, Lee JH, Shih NJ, Chen M, Terasaki PI. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antibody specificities. Transplantation75, 43–49 (2003).
   PubMed Web of Science ®Google Scholar
• Arnold ML, Pei R, Spriewald B, Wassmuth R. Anti-HLA class II antibodies in kidney retransplant patients. Tissue Antigens65(4), 370–378 (2005).
   PubMedGoogle Scholar
• Mizutani K, Terasaki P, Rosen A et al. Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am. J. Transplant.5(9), 2265–2272 (2005).
   PubMed Web of Science ®Google Scholar
• Langan LL, Park LP, Hughes TL et al. Post-transplant HLA class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival. Am. J. Transplant.7(4), 847–856 (2007).
   PubMed Web of Science ®Google Scholar
• Pollinger HS, Stegall MD, Gloor JM et al. Kidney transplantation in patients with antibodies against donor HLA class II. Am. J. Transplant.7, 857–863 (2007).
   PubMedGoogle Scholar
• Schreuder GM, Hurley CK, Marsh SG et al. The HLA dictionary 1999: a summary of HLA-A, -B, -C, -DRB1/3/4/5, -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR and -DQ antigens. Tissue Antigens54(4), 409–437 (1999).
   PubMedGoogle Scholar
• Bodmer JG, Marsh SG, Albert ED et al. Nomenclature for factors of the HLA system, 1994. Tissue Antigens44(1), 1–18 (1994).
   PubMed Web of Science ®Google Scholar
• Zachary AA, Braun WE. Calculation of a predictive value for transplantation. Transplantation39, 316–318 (1985).
   PubMedGoogle Scholar
• Zachary AA, Steinberg AF. Statistical analysis and applications of HLA population data. In: Manual of Clinical Laboratory Immunology (5th Edition). Rose NR, de Marcario EC, Folds JD, Lane HC, Nakamura RM (Eds). ASM Press, Washington, DC, USA 132–140 (1997).
   Google Scholar
• Doxiadis II, De Meester J, Smits JM et al. The impact of special programs for kidney transplantation of highly sensitized patients in Eurotransplant. Clin. Transpl.115–120 (1998).
   PubMedGoogle Scholar
• Claas FH, van Rood JJ. The hyperimmunized patient: from sensitization toward transplantation. Transpl. Int.1(2), 53–57 (1988).
   PubMedGoogle Scholar
• Claas FH, van Leeuwen A, van Rood JJ. Hyperimmunized patients do not need to wait for an HLA identical donor. Tissue Antigens34(1), 23–29 (1989).
   PubMedGoogle Scholar
• Bray RA, Nolen JD, Larsen C et al. Transplanting the highly sensitized patient: The Emory Algorithm. Am. J. Transplant.6(10), 2307–2315 (2006).
   PubMed Web of Science ®Google Scholar
• Bielmann D, Hönger G, Lutz D, Mihatsch MJ, Steiger J, Schaub S. Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. Am. J. Transplant.7(3), 626–632 (2007).
   PubMedGoogle Scholar
• Leffell MS, Montgomery RA, Zachary AA. The changing role of antibody testing in transplantation. Clin. Transpl.259–271 (2005).
   PubMedGoogle Scholar
• Zangwill S, Ellis T, Stendahl G, Zahn A, Berger S, Tweddell J. Practical application of the virtual crossmatch Pediatr. Transplant.11(6), 650–654 (2007).
   Google Scholar
• Satoskar AA, Lehman AM, Nadasdy GM et al. Peritubular capillary C4d staining in late acute renal allograft rejection – is it relevant? Clin. Transplant.22(1), 61–67 (2008).
   PubMed Web of Science ®Google Scholar
• Kawamura N, Tomita M, Hasegawa M et al. Complement C4d deposition in transplanted kidneys: preliminary report on long-term graft survival. Clin. Transplant.19(Suppl. 14), 27–31 (2005).
   PubMedGoogle Scholar
• Lefaucheur C, Nochy D, Hill GS et al. Determinants of poor graft outcome in patients with antibodymediated acute rejection. Am. J. Transplant.7(4), 832–841 (2007).
   PubMed Web of Science ®Google Scholar
• Cai J, Terasaki PI. Humoral theory of transplantation: mechanism, prevention, and treatment. Hum. Immunol.66(4), 334–342 (2005).
   PubMedGoogle Scholar
• Schönemann C, Lachmann N, Kiesewetter H, Salama A. Flow cytometric detection of complement-activating HLA antibodies. Cytometry B Clin. Cytom.62(1), 39–45 (2004).
   PubMedGoogle Scholar
• Bartel G, Wahrmann M, Exner M et al. In vitro detection of C4d-fixing HLA alloantibodies: associations with capillary C4d deposition in kidney allografts. Am. J. Transplant.8(1), 41–49 (2008).
   PubMedGoogle Scholar
• Smith D, Hamour IM, Banner NR, Rose ML. C4d fixing, luminex binding antibodies – a new tool for prediction of graft failure after heart transplantation. Am. J. Transplant.7(12), 2809–2815 (2007).
   PubMed Web of Science ®Google Scholar
• Zou Y, Stastny P, Süsal C, Döhler B, Opelz G. Antibodies against MICA antigens and kidney-transplant rejection. N. Engl. J. Med.357(13), 1293–1300 (2007).
   PubMed Web of Science ®Google Scholar
• Mizutani K, Terasaki P, Bignon JD et al. Association of kidney transplant failure and antibodies against MICA. Hum. Immunol.67(9), 683–691 (2006).
   PubMedGoogle Scholar